Net Cash Provided by (Used in) Operating Activities of BridgeBio Oncology Therapeutics, Inc. from 31 Mar 2024 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Summary
BridgeBio Oncology Therapeutics, Inc. annual and quarterly Net Cash Provided by (Used in) Operating Activities in USD history and change rate from 31 Mar 2024 to 31 Dec 2025.
  • BridgeBio Oncology Therapeutics, Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending 31 Mar 2025 was $734,642, a 19% decline year-over-year.
  • BridgeBio Oncology Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2025 was $113,894,000, a 107% decline from 2024.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Change (%)
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Change (%)

BridgeBio Oncology Therapeutics, Inc. Annual Net Cash Provided by (Used in) Operating Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $113,894,000 -$58,867,000 -107% 01 Jan 2025 31 Dec 2025 10-K 05 Mar 2026 2025 FY
2024 $55,027,000 01 Jan 2024 31 Dec 2024 10-K 05 Mar 2026 2025 FY

BridgeBio Oncology Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Operating Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $734,642 -$116,643 -19% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q1 2024 $617,999 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.